Xilis Raises $70 Million to Advance Diagnostic Platform

Aitechpark12 Jul, 2021Technology

? Xilis? MicroOrganoSphere? (MOS) technology generates thousands of miniature patient- derived tumors that capture the original heterogeneity and microenvironment for therapeutic profiling ? ? The company?s platform can deliver personalized precision treatment strategies for patients and accelerate drug discovery and development for pharmaceutical companies ? Xilis, Inc., a pioneering company using its MicroOrganoSphere (MOS) technology to guide precision therapy for cancer patients and accelerate drug discovery and development, today announced the close of a $70 million Series A financing. The round was led by Mubadala Capital, joined by new investors including GV (formerly Google Ventures), LSP (one of Europe?s largest healthcare investment firms), Catalio Capital Management, and Duke Angel Network. Current investors Felicis Ventures, Two Sigma Ventures, Pear VC, KdT Ventures, and Alix Ventures also participated.